scholarly journals Soft Tissue Wound Healing by Laser

2018 ◽  
Vol 3 (1) ◽  
Keyword(s):  
Pressure Ulcers ◽  
Monochromatic Light ◽  
Placebo Treatment ◽  
Treated Group ◽  
Healing Time ◽  
Blind Study ◽  
Controlled Study ◽  
Double Blind Study ◽  
Double Blind ◽  
Ulcer Area

Background: In 1967 a few years after the first working laser was invented, Endre Mester in Semmelweis University Budapest, Hungary wanted to find out if laser might cause cancer. He took some mice, shaved the hair off their backs, divided them into two groups and gave a laser treatment with a low powered ruby laser to one group. They did not get cancer and to his surprise the hair on the treated group grew back more quickly than the untreated group. That was how “laser biostimulation” effects were discovered. (Effect of laser on hair Growth of mice (in Hungarian). Mester, E. Szende, B. and Tota, J.G. (1967). Kiserl Orvostud 19. 628- 631). Purpose of the work: The effects of pulsed monochromatic light, with fixed pulsations and wavelengths, on the healing of pressure ulcers were evaluated in this prospective, randomized, controlled study. Method: A placebo-controlled, double-blind study using low energy photon therapy (LLLT) was performed in ten patients with bedsore on the back. Treatment was given three times a week for 10 weeks, using monochromatic (red) optical sources; diode 660nm (GaAl- 660). The patients who were randomized to placebo treatment received sham therapy from an identicalappearing light source from the same delivery system. Results: Ten patients with bedsore were randomized to receive LLLT or placebo therapy. At the conclusion of the study, the percentage of the initial ulcer area remaining unhealed in the LLLT and placebo groups was 24.4% and 84.7%, respectively (P = 0.0008). The decrease in ulcer area (compared to baseline) observed in the LLLT and placebo groups was 193.0 mm2 and 14.7 mm2, respectively (P = 0.0002). One patient dropped out of the study, complaining of lack of treatment efficacy; he was found to be randomized to the placebo group. There were no adverse effects. Conclusions: In this placebo-controlled, double-blind study LLLT was an effective modality for the treatment of bedsore which were resistant to conventional medical management. The results are encouraging as pulsed monochromatic light increased healing rate and shortened healing time. This will positively affect the quality of life in elderly patients with pressure ulcers.

A double blind randomized placebo controlled study of cholera treatment with highly diluted and succussed solutions

1994 ◽  
Vol 83 (03) ◽  
pp. 132-134 ◽  
Author(s):  
D. Jeulin ◽  
P. Peycru ◽  
C. Amengual ◽  
C. Gaucher
Keyword(s):  
Pilot Study ◽  
Placebo Treatment ◽  
Blind Study ◽  
Controlled Study ◽  
Double Blind Study ◽  
Double Blind ◽  
Technical Problems

AbstractA pilot study of homoeopathic treatment of cholera during an epidemic in Peru appeared to show that it was effective. A subsequent double blind study showed no difference betwen active homoeopathic treatment and placebo treatment. Various technical problems were encountered.

Comparison of a New Hypnotic (Finorgal) with Placebo in a Double-Blind Trial

1979 ◽  
Vol 7 (5) ◽  
pp. 387-390
Author(s):  
Gianni Baiotti
Keyword(s):  
Placebo Treatment ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial ◽  
The Mean ◽  
Mean Time

The hypnotic effects of Finorgal (ethchlorvynol with diphenhydramine) were compared with those of placebo in a double-blind study with crossover of treatments in thirty-five hospital in-patients. During the four-week period of Finorgal treatment there was a significant reduction in the mean time elapsing between the administration of the hypnotic and the onset of sleep, and a significant increase in the duration of sleep, compared with the four weeks of placebo treatment. There was also a significant increase in the proportion of nights when the patients felt they had slept well, and in the incidence of morning ‘hangover’ and nocturnal confusion during the Finorgal treatment periods. Patients had to be actively woken in the morning significantly more often following Finorgal administration. In patients experiencing pain in the night there was a significant reduction in the occurrence of pain during the nights when Finorgal had been given.

A Double-Blind Out-Patient Trial of Indalpine vs Mianserin

1985 ◽  
Vol 147 (3) ◽  
pp. 306-309 ◽  
Author(s):  
G. J. Naylor ◽  
B. Martin
Keyword(s):  
Side Effects ◽  
Treated Group ◽  
Blind Study ◽  
Antidepressant Effect ◽  
Double Blind Study ◽  
Double Blind ◽  
Significant Difference

SummaryIndalpine 150 mg per day and mianserin 60 mg per day were compared in a double-blind study of 65 depressed out-patients: 52 patients completed the 4-week trial. At the end of four weeks there was no significant difference in antidepressant effect between the two drugs; but in the first two weeks, improvement in the mianserin-treated group was significantly greater than that in the indalpine group. The mianserin-treated group reported more side-effects of sedation (eg. drowsiness, clumsiness, heaviness of limbs etc.) and one patient on indalpine developed a mild leucopenia.

scholarly journals Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study

2018 ◽  
Vol 78 (2) ◽  
pp. 179-185 ◽  
Author(s):  
Danielle M Gerlag ◽  
Mary Safy ◽  
Karen I Maijer ◽  
Man Wai Tang ◽  
Sander W Tas ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
At Risk ◽  
B Cell ◽  
Placebo Treatment ◽  
Treated Group ◽  
Controlled Study ◽  
Single Infusion ◽  
Double Blind ◽  
To Receive

ObjectivesWe explored the effects of B-cell directed therapy in subjects at risk of developing autoantibodypositive rheumatoid arthritis (RA), who never experienced inflammatory arthritis before, and explored biomarkers predictive of arthritis development.MethodsIndividuals positive for both anti-citrullinated peptide antibodies and rheumatoid factor but without arthritis were included in a randomised, double-blind, placebo-controlled study to receive a single infusion of 1000 mg rituximab or placebo.ResultsEighty-one individuals received treatment and were followed up for a mean of 29.0 (0–54) months, during which 30/81 (37%) individuals developed arthritis. The observed risk of developing arthritis in the placebo-treated group was 40%, which was decreased by 55% (HR 0.45, 95% CI 0.154 to 1.322) in the rituximab-treated group at 12 months. Rituximab treatment caused a delay in arthritis development of 12 months compared with placebo treatment at the point when 25% of the subjects had developed arthritis (p<0.0001). Erythrocyte sedimentation rate and the presence of anti-citrullinated α-enolase peptide 1 at baseline were significant predictors of arthritis development.ConclusionsA single infusion of 1000 mg rituximab significantly delays the development of arthritis in subjects at risk of developing RA, providing evidence for the pathogenetic role of B cells in the earliest, prearthritis stage of autoantibody positive RA.

A Controlled Comparison of Fluoxetine and Amitriptyline in Depressed Out-patients

1987 ◽  
Vol 151 (3) ◽  
pp. 337-340 ◽  
Author(s):  
J. P. R. Young ◽  
A. Coleman ◽  
M. H. Lader
Keyword(s):  
Sleep Disturbances ◽  
Treated Group ◽  
Blind Study ◽  
Serotonin Uptake ◽  
Dry Mouth ◽  
Selective Serotonin ◽  
Double Blind Study ◽  
Double Blind ◽  
Uptake Inhibitor ◽  
Serotonin Uptake Inhibitor

Fluoxetine, a selective serotonin uptake inhibitor (mean dose 73 mg each morning) was compared with amitriptyline (mean dose 122 mg at night) in a double-blind study of 64 depressed out-patients. Fifty patients completed the 6-week trial. The drugs did not differ with respect to psychiatrists' ratings, but amitriptyline was slightly superior with respect to patients' ratings. The amitriptyline-treated group had complaints of dry mouth and dizziness on standing; the fluoxetine-treated group of sleep disturbances, nausea, and headaches.

Consistent Efficacy and Tolerability of Almotriptan in the Acute Treatment of Multiple Migraine Attacks: Results of a Large, Randomized, Double-Blind, Placebo-Controlled Study

Cephalalgia ◽  
2000 ◽  
Vol 20 (6) ◽  
pp. 588-596 ◽  
Author(s):  
J Pascual ◽  
RM Falk ◽  
F Piessens ◽  
A Prusinski ◽  
P Docekal ◽  
...  
Keyword(s):  
Acute Treatment ◽  
Placebo Treatment ◽  
Controlled Study ◽  
Double Blind Study ◽  
Moderate Pain ◽  
Post Dose ◽  
Double Blind ◽  
Treatment Groups ◽  
Severe Intensity ◽  
Consistent Response

In this double-blind study, the efficacy and tolerability of a single dose of almotriptan (6.25 or 12.5 mg) was compared with placebo in the treatment of three consecutive migraine attacks of moderate or severe intensity. Of 1013 randomized patients, 722 evaluable patients completed the study. The total number of attacks relieved (severe or moderate pain reduced to mild or no pain) at 2 h post-dose was significantly higher ( P < 0.001) after treatment with almotriptan 6.25 or 12.5 mg compared with placebo (60% and 70% vs. 38%, respectively). Moreover, a consistent response was achieved across and within patients for almotriptan 6.25 or 12.5 mg compared with placebo (pain relief in at least two out of three attacks within 2 h for 64% and 75% vs. 36%, respectively) and less than one-third of the patients relapsed within 24 h. Almotriptan was well tolerated with no significant differences between the almotriptan and placebo treatment groups in the percentage of patients reporting adverse events. Overall, the 12.5-mg dose was associated with the most favourable efficacy/tolerability ratio and is, therefore, the recommended dose.

scholarly journals Compound Danshen Dripping Pill for Treating Early Diabetic Retinopathy: A Randomized, Double-Dummy, Double-Blind Study

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Dan Luo ◽  
Yali Qin ◽  
Wei Yuan ◽  
Hui Deng ◽  
Youhua Zhang ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Visual Field ◽  
Treated Group ◽  
Blind Study ◽  
Fundus Photography ◽  
Control Group ◽  
Therapeutic Effects ◽  
Double Blind Study ◽  
Calcium Dobesilate ◽  
Double Blind

This randomized, double-dummy, double-blind study was to observe the therapeutic effects of compound Danshen dripping pill (CDDP) in treating early diabetic retinopathy (DR). All the 57 type 2 diabetes cases in nonproliferative diabetic retinopathy (NPDR) stage were divided into two groups randomly: 28 cases treated with CDDP as the treated group and 29 cases treated with calcium dobesilate as the control group. The best corrected visual acuity (BCVA) in the treated group was significantly improved after treatment when compared to that before treatment (P<0.05). Mean defect (MD) of visual field, hemorrhage area of the fundus, microaneurysm number, fluorescent leakage area, and capillary nonperfusion area evaluated by visual field, fundus photography, and fundus fluorescein angiography in the treated group had the same results as BCVA. However, there was no statistical difference in each index between the two groups. No obvious adverse events with clinical significance occurred. Our present study showed that CDDP has a similar improvement and safety to calcium dobesilate for NPDR. In future DR treatments, CDDP may function as the auxiliary drug.

Treatment of Thrombosis of the Central Retinal Vein with Streptokinase

1968 ◽  
Vol 20 (03/04) ◽  
pp. 415-419 ◽  
Author(s):  
G. J. H den Ottolander ◽  
A Craandijk
Keyword(s):  
Visual Acuity ◽  
Treated Group ◽  
Heparin Therapy ◽  
Blind Study ◽  
Fluorescence Angiography ◽  
Double Blind Study ◽  
Double Blind ◽  
Streptokinase Therapy ◽  
Central Retinal Vein ◽  
Retinal Vein Occlusions

SummaryIn a double blind study of 5 heparin treated and 5 streptokinase treated patients with central retinal vein occlusions it would seem from the results based on visual acuity, ERG and EOG and fluorescence angiography that the heparin treated group were better off than the SK treated patients.It therefore seems dubious whether streptokinase therapy affords such an important advantage over the convential heparin therapy in cases of central retinal vein occlusions. It must be stressed that a group of 10 patients is very small and that the observations made are probably not statistically significant.

A Randomized Double-Blind Placebo-Controlled Study of Dipyrone and Aspirin in Post-Operative Orthopaedic Patients

1986 ◽  
Vol 14 (2) ◽  
pp. 63-66 ◽  
Author(s):  
S D Mehta
Keyword(s):  
Pain Relief ◽  
Closed Reduction ◽  
Blind Study ◽  
Controlled Study ◽  
Double Blind Study ◽  
Long Bones ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Orthopaedic Patients ◽  
Post Operative Pain

Two hundred and fifty-four patients with post-operative pain following closed reduction of fractured long bones completed a double-blind study of dipyrone and aspirin. Compared with placebo both active treatments produced significant relief of pain, which was apparent 30 minutes after ingestion and was maintained for the 6-hour duration of the study. Dipyrone 500 mg produced significantly greater pain relief than aspirin 500 mg. Both drugs were generally well tolerated.

Sign in / Sign up

Export Citation Format

Share Document